Smith & Nephew Plc
26 September 2000
INVESTOR VISIT TO SMITH & NEPHEW US FACILITIES
Smith & Nephew, the global medical devices company, today commenced two days
of visits by institutional investors and analysts to the US facilities of two
of its major businesses. The visit includes the Boston, Massachusetts base of
the company's endoscopy business, and the Memphis, Tennessee facilities of its
orthopaedics business. During the visit, guests will have the opportunity to
meet the senior management of both businesses, visit manufacturing facilities
and receive presentations on new and existing products. The visit is being
hosted by Chief Executive, Chris O'Donnell and Group Finance Director, Peter
Hooley.
Smith & Nephew confirmed at the start of the visit that negotiations with
Beiersdorf AG to create a global joint venture of the two companies'
traditional wound healing, casting, bandaging and phlebology operations and
for Smith & Nephew to acquire Beiersdorf's advanced woundcare business are
progressing well and should be completed within the next few weeks.
Enquiries:
Margaret Stewart, Group Director,
Corporate Affairs Tel: +44 (0) 207 401 7646
Smith & Nephew plc Fax: +44 (0) 207 930 2350
David Yates Tel: +44 (0) 171 831 3113
Financial Dynamics Fax: +44 (0) 171 831 6341
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.